Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
We prospectively studied the in vivo dialytic clearance of iron after deferoxamine (DFO) administration in four stable iron-overloaded chronic hemodialysis patients by quantifying iron concentration in blood entering and leaving the dialyzer and in dialysate after infusions of DFO. No significant arteriovenous iron differences were demonstrated. The mean ratio of venous to arterial iron approached identity at 1.005. All dialysate concentrates used contained large amounts of iron (300-610 micrograms/dl). No changes in efferent versus afferent dialysate iron concentration could be demonstrated. We conclude (a) iron removal during dialysis with DFO was not demonstrated; (b) the dialysate concentrate tested contained large amounts of iron; (c) in view of potentially significant toxicity, and lack of demonstrable therapeutic benefit, caution in prescribing DFO chelation therapy for iron overload is recommended.
Roxe
D M
DM
Department of Medicine, Northwestern University Medical School, Chicago, Illinois.
Krumlovsky
F A
FA
Del Greco
F
F
Fitzsimons
E
E
D003676:Deferoxamine / Q000627:therapeutic use*; D015314:Dialysis Solutions / Q000032:analysis*; D006486:Hemosiderosis / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007501:Iron / Q000032:analysis*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008134:Long-Term Care; D008657:Metabolic Clearance Rate; D011446:Prospective Studies; D006435:Renal Dialysis / Q000009:adverse effects; D012189:Retrospective Studies
D015314:Dialysis Solutions; D007501:Iron; D003676:Deferoxamine